

Immunoglobulins of Newborns Who Underwent Intrauterine Transfusion in the Antenatal Period

Salimova K. A., Jabborov U. U.

Republican Perinatal Center, Tashkent, Uzbekistan

Abstract To study the indices of innate humoral immunity such as immunoglobulins G, M, A in umbilical cord blood of newborns with haemolytic disease who underwent high-tech fetal surgeries during pregnancy. The studies were conducted at the Republican Perinatal Center in 2024. A total of 70 newborns participated in the study and were divided into 3 groups. 1st main group of 25 newborns with haemolytic disease and who underwent ‘intrauterine, intravascular haemotransfusion to fetus’ operation in antenatal period, 2nd comparison group of 25 newborns with haemolytic disease and who did not undergo fetal surgery in antenatal period and 3rd control group of 20 healthy newborns. Immunological studies were done at the Institute of Immunology of the Academy of Sciences of the Republic of Uzbekistan. IgG in newborns in the comparison group was significantly increased 1.4 times in relation to the control group, and IgA and IgM were also significantly increased 2.3 times and 2.2 times in relation to healthy newborns. IgG, A, M indices in the main group of newborns where fetal technology was performed were not significantly different from those of the healthy control group. Fetal technologies not only improve haematological indices of fetal blood, but also improve the indices of humoral immunity of the newborn after birth, in particular, contribute to the decrease in the level of IgG, A and M. All this indicates a decrease in the inflammatory potential and prevents the formation of immunodeficiency state at birth.

Keywords Immunoglobulins G, M, A, Rh-immunisation, Haemolytic disease of the newborn (HDN), Intrauterine blood transfusion (IUT)

1. Introduction

Intrauterine intravascular blood transfusion (IVF) remains the principal therapeutic intervention for severe fetomaternal anemia secondary to Rhesus immunization. As the destruction of fetal red blood cells happens due to maternal antibodies, the procedure is necessary to replace lost blood and to prevent anemia and complications related to that. Fetal humoral immunity and its immunological effectiveness of GDP has recently been focused on. VVPC is primarily aimed at replenishing the fetal red blood cell deficiency due to hemolysis and preventing the subsequent deterioration of anemia and its complications. This process is typically done via umbilical cord vein under ultrasound guidance. The indication for MIC according to the researchers is severe fetal anemia, which is characterized by hematocrit below 15-25% in relation to normal for gestational age as well as hemoglobin levels below 80-90 g/l [1,2,3].

The best hematological parameters of offspring are found in newborns delivered to patients who had undergone intrauterine intravascular transfusion (IVF) for rhesus alloimmunization,

according to data published internationally [4]. Existing studies of perinatal outcomes in cases of severe erythrocyte alloimmunization treated with IUT have mainly centered around the perinatal survival outcome after IUT. Most of these studies were performed in developed countries. Limited studies have evaluated the effect of IUT on newborn clinical outcomes postnatally. Furthermore, data on fetal and neonatal outcomes in women with a diagnosis of rhesus conflict that underwent intrauterine transfusion (IUT) in developing countries are very scarce [5,6,7].

Most studies of transfusion-induced immunological modulation have been performed in adult patients and children in intensive care settings. Under the perspective of encompassing the physiology of the maternal-fetal interface and intrauterine tolerance, the features of the development of fetal immune response in presence of allogeneic donor erythrocytes, and its implications on transplantation, preservation of erythrocytes, and effectiveness of intrauterine blood transfusions remain unanswered. [8,9,10].

The aim of the study: was comparative assessment of humoral immunity factors (G, M and A immunoglobulins), as well as in the cord blood of newborns with hemolytic disease of the newborn caused by rhesus-conflict in pregnant women who have undergone in utero therapeutic ecos-peritoneal and intrauterine intravascular blood transfusion to the fetus.

2. Research Materials

The research was conducted on a total of 70 newborns born at the Republican Perinatal Center in 2024. They were separated into 3 classes. The 1st main group included 25 newborns with hemolytic disease, who underwent the operation "intrauterine, intravascular hemotransfusion to the fetus" during the antenatal period, the 2nd comparison group included also 25 newborns with hemolytic disease, who did not undergo fetal surgery in the antenatal period, and the 3rd control group included 20 healthy newborns.

Immunological research methods: the newborn immune status studies were carried out on and cord blood on the 1st day of life in the Laboratory of Fundamental Immunology in Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan.

Levels of the basic immunoglobulin and cytokines in biological fluids were determined by way of enzyme immunoassay (ELISA) using commercial Human test systems (Germany). The test systems are based on solid-phase enzyme immunoassay using horseradish peroxidase as an indicator enzyme of the sandwich method. Reagent kits are a set, wherein the principal reagents are MCATs for the studied cytokines, sorbed on a surface of hills of a collapsible polystyrene tablet. The kits are for the quantitative determination of human cytokines in peripheral blood serum and in

biological fluids. The optical density of the wells was read at 450 nm using an automatic photometer for microplates (Stat-Fax analyzer, USA) by enzyme immunoassay.

Statistical analysis of results was performed by parametric and nonparametric methods. The information was accumulated, corrected, systematized and the results were visualized in Microsoft Office Excel 2018 spreadsheets. The statistical analysis was performed using the IBM SPSS Statistics v.26 software (IB-M Corp, Armonk, NY). For normally distributed quantitative data sets, the Student's t-test was calculated for the comparison of averages. The values of Student's t-test obtained were assessed against critical values. Differences in the indicators were considered statistically significant $p < 0.05$.

3. Result and Discussion

Implementing an immunological examination and validating the effectiveness of intrauterine intravascular fetal hemotransfusion provided an evaluation of humoral immunity in neonates on background of fetal surgery. To this end, immunological studies of humoral immunity in the umbilical cord blood of newborns with HDN, who have undergone intrauterine hemotransfusion, were carried out, and who have not undergone hemotransfusion. The results are depicted below in Table 1.

Table 1. The main humoral parameters of newborn immunity (umbilical cord blood), (M \pm m, g/l)

Parameters	Main group (n-25)	Comparison group (n-25)	The control group (n-20)
Immunoglobulin G	7,33 \pm 0,75 ^	8,51 \pm 1,21 *	6,36 \pm 0,35
Immunoglobulin A	1,53 \pm 0,32 ^	2,95 \pm 0,24 *	1,28 \pm 0,44
Immunoglobulin M	1,64 \pm 0,50 * ^	2,26 \pm 0,45 *	1,05 \pm 0,45

Note : * – the significant of differences with the control group is $p < 0,05$;

^ - the reliability of differences between the studied group

IgG class antibodies can use transplacental transport, so the immune factors of mother and fetus can be continuously related. Thus, the analysis indicated that the values of immunoglobulin G in umbilical cord blood of newborns in the comparison group significantly increased by 1.4 times ($p < 0.05$) comparative to the control group while IgG in umbilical cord blood of newborns in the main group was not significantly increased in comparison with the control group. The comparison between the two study groups showed that the immunoglobulin G index in the main group after hemotransfusion decreased statistically significantly ($p < 0.05$) in comparison with the comparison group and the indicator decreased by 1.2 times.

The level of immunoglobulin A in umbilical cord blood in the group of newborns without intrauterine hemotransfusion was significantly increased 2.3 fwd average D relative to the control group.

The umbilical cord blood immunoglobulin A levels in neonatal patients after intrauterine hemotransfusion were not statistically increased in comparison with the control group. According to comparison of differences between both study groups, in an experimental group of neonates the concentration

of immunoglobulin A is lower - in 1,9 times than in comparison group of neonates.

About 18-20 weeks of gestation, IgM are the first immunoglobulins to be synthesized in the fetus. They form first in their first collision with the IgM antigen, but they exist in lesser amounts in subsequent collisions. IgMs cannot cross the placenta.

The level of immunoglobulin M in the umbilical cord blood of newborns from the comparison group, that is, who underwent pregnancy in the classical way was significantly higher by 2.2 times in comparison with the control group, while the IdM was significantly higher in the umbilical cord blood of newborns after fetal surgery, that is, in the main group by 1.6 times in comparison with the control group. Immunoglobulin M decreases slightly in the main group (after intrauterine hemotransfusion), similar significant difference with respect to the comparison group in 1.4 times.

It is clear from the data that in this study, in response to the antenatal background of intrauterine and intravascular hemotransfusion to the fetus, there is a maturation of humoral immunity factors in the newborn. It should be noted that the concentrations of the studied immunoglobulins in the newborn

after birth are improved after intrauterine hemotransfusion. As we can see, the level of immunoglobulins G, A and M, decreases, – all it indicates a decrease in the inflammatory potential after hemotransfusions.

4. Conclusions

1. Umbilical cord blood IgG index was not significantly increased in the main group newborns who received fetal technologies during the antenatal period against the group of healthy newborns.
2. In the umbilical cord blood of newborns not subjected to intrauterine hemotransfusion of the antenatal period, IgA, increased 2.3 times compared to the control group and IgA was not increased in newborns in the main group.
3. The level of IgM in the umbilical cord blood of newborns of the comparison group, i.e., where pregnancy occurred traditionally significantly increased 2.2 times compared with the control group.
4. Hemotransfusion of the fetus, intrauterine, through the blood stream also led to an improvement in fetal blood hematological parameters and to humoral immunity changes, particularly a need from immunoglobulins G, A, M. All of this indicates a reduced inflammatory potential and prevents the formation of an immunodeficiency state at birth.

REFERENCES

- [1] Kerimova E.A., Putilova N.V., Chistyakova G.N., Pestryaeva L.A., Ustyantseva N.Yu. Clinical and immunological substantiation of intrauterine hemotransfusions in fetal hemolytic disease according to the rhesus system <https://dx.doi.org/10.18565/aig.2016.12.24-7>.
- [2] Crawford T.M., Andersen C.C., Hodyl N.A. et al. Effect of washed versus unwashed red blood cells on transfusion-related immune responses in preterm newborns. *Clin. Transl. Immunology*. 2022; 11(3): e1377. DOI: 10.1002/cti2.1377.
- [3] Dani C., Poggi C., Gozzini E. et al. Red blood cell transfusions can induce proinflammatory cytokines in preterm infants. *Transfusion*. 2017; 57(5): 1304–1310. DOI: 10.1111/trf.14080.
- [4] David Baptista da Silva Pares, Gilda Helena Arruda Sousa Pacheco, Guilherme Antonio Rago Lobo, Edward Araujo Júnior. Intrauterine Transfusion for Rhesus Alloimmunization: A Historical Retrospective Cohort from A Single Reference Center in Brazil. *Journal of clinical medicine, J. Clin. Med.* 2024, 13(5), 1362; <https://doi.org/10.3390/jcm13051362>.
- [5] Ghesquiere L, Garabedian C, Coulon C, Verpillat P, Rakza T, Wibaut B, Delsalle A, Subtil D, Vaast P, Debarge V. Management of red blood cell alloimmunization in pregnancy. *J Gynecol Obstet Hum Reprod*. 2018; 47:5:197-204.
- [6] Remy K.E., Hall M.W., Cholette J. et al. Mechanisms of red blood cell transfusion-related immunomodulation. *Transfusion*. 2018; 58(3): 804–815. DOI: 10.1111/trf.14488.
- [7] Sainio S, Nupponen I, Kuosmanen M, Aitokallio-Tallberg A, Ekholm E, Halmesmaki E, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. *Acta Obstet Gynecol Scand*. (2015) 94:383–90. doi: 10.1111/aogs.12590.
- [8] Tiblad E, Kublickas M, Ajne G, Bui TH, Ek S, Karlsson A, et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. *Fetal Diagn Ther*. (2011) 30: 266–73. doi: 10.1159/000328683.
- [9] Urutherakumar V, Welsh A, Henry A. Short-term outcomes following intrauterine transfusions for fetal anaemia: a retrospective cohort study. *Aust N Z J Obstet Gynaecol*. (2020) 60:738–45. doi: 10.1111/ajo.13155.
- [10] Zwiers C., Oepkes D., Lopriore E., Klumper F., Haas M., Van Kamp I. The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization. *Prenat. Diagn*. 2018, 38, 943–950.